NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.02. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ovid Therapeutics.

7 Wall Street analysts have issued 12-month price targets for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $27.00. On average, they anticipate Ovid Therapeutics' stock price to reach $14.80 in the next year. This suggests a possible upside of 287.4% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

Press coverage about OVID stock has been trending neutral on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ovid Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 858,500 shares, an increase of 5.8% from the January 15th total of 811,800 shares. Based on an average daily volume of 727,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 4.0% of the company's stock are sold short. View Ovid Therapeutics' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), AcelRx Pharmaceuticals (ACRX), Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Opko Health (OPK), Sorrento Therapeutics (SRNE), Verastem (VSTM) and Actinium Pharmaceuticals (ATNM).

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (4.36%), Renaissance Technologies LLC (2.27%), BVF Inc. IL (1.54%), Citigroup Inc. (1.05%), Ikarian Capital LLC (0.73%) and Platinum Investment Management Ltd. (0.64%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Acadian Asset Management LLC. View Insider Buying and Selling for Ovid Therapeutics.

OVID stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Citigroup Inc., Renaissance Technologies LLC, Ikarian Capital LLC, Credit Suisse AG, Blair William & Co. IL, Platinum Investment Management Ltd. and Laurion Capital Management LP. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $3.82.